Phaseline

Companies › Colgate Palmolive

Colgate Palmolive: clinical trials, targets and expected readouts

8 active drug programs in 10 registered trials: 8 Phase 3, 2 Phase 4; Gastroenterology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Test Mouthrinse
Antimicrobial mouthrinse containing fluoride and zinc lactate for plaque reduction and gum
–Phase 4GingivitisNov 2026
sodium monofluorophosphate toothpaste
Fluoride source for dental remineralization and caries prevention
ENPP1Phase 4Gingivitis–
Colgate SNaP Total 10/10, 1.5 Taurate
Stannous fluoride toothpaste (0.454% SnF, 1100 ppm F) with taurate
UNKNOWNPhase 3Plaque, DentalNov 2026
0.45% SnF HW with NaF (1450 F)
Stannous fluoride with sodium fluoride for topical fluoride delivery and antimicrobial act
SLC5A1Phase 3PlaqueJan 2027
67% Bicarbonate with NaF (1400 F)
Sodium bicarbonate with sodium fluoride for plaque reduction
–Phase 3PlaqueJan 2027
0.412% stannous fluoride toothpaste
Topical fluoride and tin for plaque and gingivitis reduction
–Phase 3PlaqueApr 2027
8% arginine + Zinc toothpaste
Dentin occluding agent containing arginine and zinc phosphate
–Phase 3Dentinal Sensitivity–
Max Fresh Toothpaste
zinc citrate for oral malodor reduction
–Phase 3Oral Malodor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07398378Max Fresh ToothpastePhase 3Oral MalodorOtherJul 2026
NCT076645928% arginine + Zinc toothpastePhase 3Dentinal SensitivityGastroenterologySep 2026
NCT076645928% arginine + Zinc toothpastePhase 3Dentinal SensitivityGastroenterologySep 2026
NCT076645928% arginine + Zinc toothpastePhase 3Dentinal SensitivityGastroenterologySep 2026
NCT07614490sodium monofluorophosphate toothpastePhase 4GingivitisGastroenterologySep 2026
NCT07414173Test MouthrinsePhase 4GingivitisGastroenterologyNov 2026
NCT07605338Colgate SNaP Total 10/10, 1.5 TauratePhase 3Plaque, DentalGastroenterologyNov 2026
NCT078429910.45% SnF HW with NaF (1450 F)Phase 3PlaqueGastroenterologyJan 2027
NCT0784299167% Bicarbonate with NaF (1400 F)Phase 3PlaqueGastroenterologyJan 2027
NCT079175070.412% stannous fluoride toothpastePhase 3PlaqueGastroenterologyApr 2027

From the company's SEC filings

Cash of $1.5bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ENPP1 (1) SLC5A1 (1) UNKNOWN (1)

Companies with the same targets

Riboscience Stingray Therapeutics Inozyme Pharma Lexicon Pharmaceuticals Vogenx General Oncology Gilead Sciences Iterum Therapeutics, International Vaxcyte Zhejiang Raygene Pharmaceuticals

Companies built like this

Procter and Gamble Norgine Elgan Pharma Cinclus Pharma Holding Polaris Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.